NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

I don't know that the criteria they used in the paper to pick the healthiest and youngest patients is similar to what NWBO used for the DCVAX Phase 3 Johnni. I suspect it is not. This topic has been brought up often on this board and always seem to end concluding they did not cherry pick the patients.
Here is a link to a post from AVII77
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163568792
You will see that out of the 1599 screened and the 1268 that rejected included things like:
306 Not GBM
201 Insufficient Tumor Lystate
61 Leukopheresis Unsuccessful
ect . . .

Even if one was to assume they did cherry pick the patients look at the table below from the paper you sent me.
It has 2 year survival at 33.3 % and 5 year at 10.9%
From the blinded data we have for DCVAX PH-3
https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/
Survival at 3 years is 28.2% (similar to the 33.3% at 2 years for the cherry picked patients)
Survival at 3 years for 41.1% (methylated)
This is all patients so I think we will still be better than the cherry picked patients in the paper.
We have not see the 5 year results for DCVAX yet but we do know that survival flattened out.
Thanks for sending.